Neuphoria Therapeutics Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
NEUP$2.69-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows (Unaudited)
| Three Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(9,906,504) | $(804,787) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Share-based compensation | 111,277 | 26,736 |
| Depreciation and amortization expense | 165,792 | 165,713 |
| Non-cash rent expense | 27,393 | 19,528 |
| Change in fair value of accompanying warrant liability | 4,390,726 | (2,966,245) |
| Change in fair value of contingent consideration | (12,763) | 91,551 |
| Effect of foreign currency remeasurement | 32,644 | 233,044 |
| Changes in assets and liabilities: | ||
| Accounts receivable, non-trade | 10,190 | 10,924 |
| Prepaid insurance expense | 517,874 | 227,657 |
| Accounts payable | 216,359 | (917,668) |
| Accrued expenses and other current liabilities | 718,261 | (367,583) |
| Operating lease liabilities | (31,104) | (20,268) |
| Deferred tax liability | (34,793) | (132,216) |
| Other non-current liabilities | - | 551 |
| Net cash used in operating activities | (3,794,648) | (4,433,063) |
| Cash flows from financing activities: | ||
| Proceeds from the sale of equity, net of issuance costs of $0.1 million | 3,253,615 | - |
| Proceeds from the exercise of pre-funded ADS warrants | - | 409 |
| Issue costs associated with ADS shares and ADS pre-funded warrants | - | (227,747) |
| Net cash provided by (used in) financing activities | 3,253,615 | (227,338) |
| Effect of exchange rate on changes on cash, cash equivalents, and restricted cash | (19,455) | 138,367 |
| Net decrease in cash, cash equivalents, and restricted cash | (560,488) | (4,522,034) |
| Cash, cash equivalents, and restricted cash, beginning of period | 14,288,690 | 12,686,935 |
| Cash, cash equivalents, and restricted cash, end of period | $13,728,202 | $8,164,901 |
| Reconciliation of cash, cash equivalents, and restricted cash: | ||
| Cash and cash equivalents | $13,649,638 | $8,082,410 |
| Restricted cash | 78,564 | 82,491 |
| Total cash, cash equivalents, and restricted cash | $13,728,202 | $8,164,901 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.